Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services informed stock exchanges that its subsidiary, Optival Health Solutions Private Limited, received a 7-day suspension order for the drug license of one store located on Chinthalapudi Road, Eluru and West Godavari District, Andhra Pradesh. The order was issued by the Assistant Director, District Sales Licensing Authority, Drugs Control Administration on February 12, 2026, under Rule 65 of the Drugs and Cosmetics Act, 1940. The company has stated that the potential revenue loss from this suspension is around Rs 4.28 lakhs. This is a routine regulatory action affecting a single store among Medplus's large pharmacy network.
The financial impact is negligible at Rs 4.28 lakhs, which is very small relative to Medplus's overall operations. Shareholders are unlikely to see any meaningful effect on the stock price, as this is a single-store, short-duration regulatory action.